Drug Type Small molecule drug |
Synonyms RO-7568282 |
Target |
Action inhibitors |
Mechanism NLRP3 inhibitors(NACHT, LRR and PYD domains-containing protein 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alzheimer Disease | Phase 2 | United States | 31 Oct 2026 | |
| Parkinson Disease | Phase 2 | United Kingdom | 30 Sep 2026 | |
| Primary Parkinson's disease | Phase 2 | United States | 20 Sep 2026 | |
| Primary Parkinson's disease | Phase 2 | China | 20 Sep 2026 |





